Variable (n) | Criterion | Frequency | % |
---|---|---|---|
Estimated number of patients with mCRC tested per year (n = 96) | >80 | 69 | 71.9 |
≤80 | 27 | 28.1 | |
Reported indication for RAS mutation testing (n = 95) | “On request from an oncologist” | 85 | 89.5 |
“All CRC patients tested” | 5 | 5.3 | |
“Other”a | 5 | 5.3 | |
Location of RAS mutation testing (n = 96) | Own institution | 90 | 93.8 |
External | 1 | 1.0 | |
Own institution and external | 5 | 5.2 | |
Minimum percentage of neoplastic cells required (n = 96) | No cut-off defined | 10 | 10.4 |
<10 % | 18 | 18.8 | |
≥10 % | 68 | 70.8 | |
DNA extraction method used (n = 96) | QIAamp DNA FFPE kit (Qiagen) | 40 | 41.7 |
Cobas DNA Sample Preparation kit (Roche) | 12 | 12.5 | |
QIAamp DNA mini kit (Qiagen) | 7 | 7.3 | |
Raw proteinase K lysate | 6 | 6.3 | |
Maxwell 16 (Promega) | 14 | 14.6 | |
MagNA Pure (Roche) | 1 | 1.0 | |
Other | 16 | 16.7 | |
RAS mutations tested (n = 96) | All codons tested | 70 | 72.9 |
Not all codons tested | 26 | 27.1 |